For the year ending 2025-12-31, SLDB had -$20,297K decrease in cash & cash equivalents over the period. -$157,442K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -174,325 |
| Amortization of discount on available-for-sale securities | 1,874 |
| Equity-based compensation expense | 16,914 |
| Depreciation and amortization expense | 1,636 |
| Non-cash lease expense | 2,371 |
| Non-cash acquired in-process research and development | 0 |
| Common stock issued as upfront payment for collaboration and license agreement | 0 |
| Change in fair value of derivative liabilities | -6,050 |
| Other | 239 |
| Prepaid expenses and other current and non-current assets | 7,993 |
| Accounts payable | -1,093 |
| Change in operating lease liability | -1,786 |
| Accrued expenses and other current and non-current liabilities | 4,050 |
| Net cash used in operating activities | -156,289 |
| Purchases of property and equipment | 1,153 |
| Proceeds from sale of property and equipment | 85 |
| Proceeds from sales and maturities of available-for-sale securities | -178,500 |
| Purchases of available-for-sale securities | 235,886 |
| Net cash used in investing activities | -58,454 |
| Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions | 189,637 |
| Payments of common stock and pre-funded warrants issuance costs in public offering | 1,681 |
| Proceeds from issuance of common stock and pre-funded warrants in private placement | 0 |
| Payments of common stock and pre-funded warrants issuance costs in private placement | 0 |
| Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions | 6,782 |
| Proceeds from exercises of common stock options | 6 |
| Employee stock purchase plan purchases | 425 |
| Payments of principal portion of finance lease obligations | 723 |
| Net cash provided by financing activities | 194,446 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -20,297 |
| Cash, cash equivalents, and restricted cash at beginning of period | 82,187 |
| Cash, cash equivalents, and restricted cash at end of period | 61,890 |